Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tebentafusp (IMCgp100) is a bispecific fusion protein designed to target the gp100 peptide-HLA-A*02:01 complex, a melanoma-associated antigen. It directs T cells towards melanoma cells expressing gp100 through a high-affinity T-cell receptor (TCR) binding domain coupled with an anti-CD3 domain, promoting T-cell engagement. This action triggers the production of inflammatory cytokines and cytolytic proteins, culminating in the direct lysis of tumor cells [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Tebentafusp (IMCgp100) is a bispecific fusion protein designed to target the gp100 peptide-HLA-A*02:01 complex, a melanoma-associated antigen. It directs T cells towards melanoma cells expressing gp100 through a high-affinity T-cell receptor (TCR) binding domain coupled with an anti-CD3 domain, promoting T-cell engagement. This action triggers the production of inflammatory cytokines and cytolytic proteins, culminating in the direct lysis of tumor cells [1] [2]. |
Molecular Weight | N/A |
CAS No. | 1874157-95-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tebentafusp 1874157-95-5 inhibitor inhibit